IMMUNEERING CORP - CLASS A (IMRX) Stock News

USA - NASDAQ:IMRX - US45254E1073 - Common Stock

6.62 USD

-0.12 (-1.78%)

Last: 11/12/2025, 8:00:02 PM

6.88 USD

+0.26 (+3.93%)

Pre-Market: 11/13/2025, 6:02:56 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IMRX Latest News, Press Relases and Analysis

All

Press Releases

15 hours ago - By: Immuneering Corporation

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

15 hours ago - By: Immuneering Corporation

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

3 days ago - By: Zacks Investment Research - Mentions: ASND AUTL ANRO

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?

9 days ago - By: Immuneering Corporation

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

2 months ago - By: Stocktwits - Mentions: SNY

News Image

Why Immuneering Stock Soared Over 40% After-Hours Today

3 months ago - By: Immuneering Corporation

Immuneering Announces Closing of $25 Million Private Placement

3 months ago - By: Stocktwits - Mentions: LLY

News Image

Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips

a day ago - By: Benzinga - Mentions: GWRS DYAI LEGN KOPN ...

Earnings Scheduled For November 12, 2025

2 days ago - By: Benzinga

A Preview Of Immuneering's Earnings

3 months ago - By: Immuneering Corporation

Immuneering Announces $25 Million Private Placement

2 months ago - By: Immuneering Corporation

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

2 months ago - By: Immuneering Corporation

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

2 months ago - By: Immuneering Corporation

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

2 months ago - By: Immuneering Corporation

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

2 months ago - By: Immuneering Corporation

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

2 months ago - By: Immuneering Corporation

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

2 months ago - By: Immuneering Corporation

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

2 months ago - By: Immuneering Corporation

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

2 months ago - By: Immuneering Corporation

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

2 months ago - By: Immuneering Corporation

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

2 months ago - By: Immuneering Corporation

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

3 months ago - By: Immuneering Corporation

Immuneering Announces Closing of $25 Million Private Placement

3 months ago - By: Zacks Investment Research - Mentions: LLY REGN

Immuneering Stock Rises 21.7% on Supply Agreement With LLY

3 months ago - By: Immuneering Corporation

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

3 months ago - By: Immuneering Corporation - Mentions: LLY

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

3 months ago - By: Immuneering Corporation

Immuneering Announces $25 Million Private Placement

3 months ago - By: The Motley Fool

Immuneering Posts Narrower Loss in Q2

3 months ago - By: Immuneering Corporation

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates